Related Experiment Video
Updated: Sep 18, 2025
08:02
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
5.5K
Dendritic Cell-Based Biohybrid Immunomodulator Alleviates Intestinal Inflammatory Disease
Wenzhe Yi1,2, Fang Sun3, Xindi Qian1
1State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Advanced Materials (Deerfield Beach, Fla.)
|June 23, 2025
Summary
A novel biohybrid immunomodulator combining dendritic cells and resolvin E1 shows promise for treating inflammatory bowel disease (IBD). This approach selectively targets and eliminates inflammatory cells, offering a new therapeutic avenue for IBD patients.
Area of Science:
- Immunology
- Gastroenterology
- Biotechnology
Background:
- Inflammatory bowel disease (IBD) is driven by intestinal inflammation, with a need for new treatments beyond biologics for non-responders.
- Current therapies have limitations, highlighting the demand for alternative strategies to manage IBD effectively.
Purpose of the Study:
- To develop and evaluate a dendritic cell (DC)-based biohybrid immunomodulator for alleviating intestinal inflammation in IBD.
- To investigate the efficacy of engineered DCs conjugated with resolvin E1-loaded liposomes in preclinical IBD models.
Main Methods:
- Engineered a biohybrid immunomodulator by conjugating Fas ligand (FasL)-transfected DCs with resolvin E1-loaded liposomes.
- Validated the immunomodulator's efficacy in mouse and rabbit models of IBD, assessing its ability to reduce inflammation.
- Confirmed the immunomodulator's capacity to induce T cell apoptosis using human cells.
Main Results:
- The biohybrid immunomodulator demonstrated significant anti-inflammatory effects in IBD models.
- It selectively eliminated Fas-expressing (Fas+) CD8+ T cells and neutrophils, key contributors to intestinal inflammation.
- The approach is manufacturable using human cells, indicating clinical feasibility.
Conclusions:
- Developed a feasible and customizable DC-based biohybrid immunomodulator for mitigating intestinal inflammation.
- This strategy offers a promising advancement for treating inflammatory bowel disease, particularly for patients unresponsive to existing therapies.
